Drug Approval | December 27, 2022
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Surana is a chartered accountant with an all-India rank.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
Post the sale, Patel family has become the single largest promoter shareholder in the company
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Move to increase affordability and accessibility for heart failure patients across the country
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Subscribe To Our Newsletter & Stay Updated
